Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
PDS Biotechnology 5.29M share Spot Secondary priced at $8.50 » 09:03
06/15/21
06/15
09:03
06/15/21
09:03
PDSB

PDS Biotechnology

$12.87 /

+0.8 (+6.63%)

The deal priced at low…

The deal priced at low end of $8.50-$9.00 range. Cantor Fitzgerald is acting as sole book running manager for the offering.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

  • 15
    Jun
  • 11
    Aug
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

Monday
On The Fly
Fly Intel: After-Hours Movers » 18:41
06/14/21
06/14
18:41
06/14/21
18:41
BBCP

Concrete Pumping

$8.54 /

+0.14 (+1.67%)

, PDSB

PDS Biotechnology

$12.87 /

+0.8 (+6.63%)

, VRM

Vroom

$45.13 /

+0.92 (+2.08%)

, CCCC

C4 Therapeutics

$42.14 /

-0.05 (-0.12%)

, CBRL

Cracker Barrel

$153.36 /

-1.92 (-1.24%)

, ABR

Arbor Realty

$19.42 /

+0.33 (+1.73%)

, FUSN

Fusion Pharmaceuticals

$8.16 /

+0.01 (+0.12%)

ShowHide Related Items >><<
VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
01/13/21 B. Riley
Concrete Pumping price target lowered to $6 from $6.75 at B. Riley Securities
01/07/21 B. Riley
Concrete Pumping price target raised to $6.75 from $6.50 at B. Riley Securities
01/05/21 Baird
Concrete Pumping upgraded to Outperform from Neutral at Baird
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
VRM Vroom
$45.13 /

+0.92 (+2.08%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

05/26/21 Truist
Cracker Barrel price target raised to $171 from $160 at Truist
04/15/21 CL King
Cracker Barrel downgraded to Neutral from Buy at CL King
04/01/21 MKM Partners
Cracker Barrel price target raised to $160 from $155 at MKM Partners
03/29/21 Deutsche Bank
Deutsche Bank starts Cracker Barrel at Buy, sees 13% share upside
ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

04/26/21 JPMorgan
Arbor Realty price target raised to $18 from $16.50 at JPMorgan
11/06/20 Wolfe Research
Arbor Realty initiated with an Outperform at Wolfe Research
07/28/20 JPMorgan
Arbor Realty upgraded to Overweight on favorable risk/reward at JPMorgan
07/28/20 JPMorgan
Arbor Realty upgraded to Overweight from Neutral at JPMorgan
FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

  • 15
    Jun
  • 15
    Jun
  • 17
    Jun
  • 26
    Mar
  • 07
    Dec
  • 11
    Nov
  • 02
    Oct
  • 11
    Sep
  • 11
    Aug
  • 26
    Jun
VRM Vroom
$45.13 /

+0.92 (+2.08%)

VRM Vroom
$45.13 /

+0.92 (+2.08%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

Syndicate
PDS Biotechnology Spot Secondary price range $8.50-$9.00 » 16:30
06/14/21
06/14
16:30
06/14/21
16:30
PDSB

PDS Biotechnology

$12.87 /

+0.8 (+6.63%)

Cantor Fitzgerald is…

Cantor Fitzgerald is acting as sole book running manager for the offering.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

  • 11
    Aug
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

Syndicate
PDS Biotechnology files to sell common stock, no amount given » 16:03
06/14/21
06/14
16:03
06/14/21
16:03
PDSB

PDS Biotechnology

$13.13 /

+1.06 (+8.78%)

Cantor Fitzgerald &…

Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$13.13 /

+1.06 (+8.78%)

PDSB PDS Biotechnology
$13.13 /

+1.06 (+8.78%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
PDSB PDS Biotechnology
$13.13 /

+1.06 (+8.78%)

  • 11
    Aug
PDSB PDS Biotechnology
$13.13 /

+1.06 (+8.78%)

Over a week ago
Recommendations
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer » 07:36
06/09/21
06/09
07:36
06/09/21
07:36
PDSB

PDS Biotechnology

$11.15 /

+1.76 (+18.74%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell raised the firm's price target on PDS Biotechnology to $25 from $12 and keeps an Outperform rating on the shares. The analyst notes that following the positive meeting abstract, an oral ASCO presentation of expanded clinical results in advanced, heavily-pretreated HPV-associated cancers strengthens PDS0101's treatment prospects for these challenging malignancies as well as further supports Versamune platform potential for broader cancer immunotherapy. Looking ahead, the data bolsters his confidence in '0101's prospects with Keytruda in the first-line treatment of recurrent/metastatic head and neck cancer, for which initial results could become available by year-end. Together with the ongoing cervical cancer trial, which adds PDS0101 to standard-of-care cisplatin/radiation therapy, these three sets of clinical study results should collectively establish a solid foundation to inform key elements of registrational trial design as well as drive interest in PDS's technology among larger oncology players, Gershell contends.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

  • 11
    Aug
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

Recommendations
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners » 07:05
06/09/21
06/09
07:05
06/09/21
07:05
PDSB

PDS Biotechnology

$11.15 /

+1.76 (+18.74%)

Alliance Global Partners…

Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
03/19/21 H.C. Wainwright
PDS Biotechnology price target raised to $8 from $6 at H.C. Wainwright
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

  • 11
    Aug
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

Recommendations
PDS Biotechnology price target raised to $15 from $11 at Chardan » 19:37
06/08/21
06/08
19:37
06/08/21
19:37
PDSB

PDS Biotechnology

$11.15 /

+1.76 (+18.74%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on PDS Biotechnology to $15 from $11 and keeps a Buy rating on the shares. The data from an NCI-led trial of PDS0101 with NHS-IL12 and M7824 presented at ASCO yesterday thus far appears to diverge in a meaningful way from relevant standard-of-care benchmarks in both immune checkpoint inhibitor (ICI)-naive and post-ICI settings, and also provides a positive read-across to the VERSATILE-002 study of PDS0101 + Keytruda in HPV16+ head and neck cancer, the analyst tells investors in a research note.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
03/19/21 H.C. Wainwright
PDS Biotechnology price target raised to $8 from $6 at H.C. Wainwright
11/10/20 H.C. Wainwright
PDS Biotechnology upgraded to Buy from Neutral at H.C. Wainwright
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

  • 11
    Aug
PDSB PDS Biotechnology
$11.15 /

+1.76 (+18.74%)

Hot Stocks
PDS Biotechnology presents interim data from Phase 2 trial on PDS0101 » 06:04
06/08/21
06/08
06:04
06/08/21
06:04
PDSB

PDS Biotechnology

$9.39 /

-3.37 (-26.41%)

PDS Biotechnology…

PDS Biotechnology announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, at the American Society of Clinical Oncology 2021 Annual Meeting. The Phase 2 trial studies PDS0101, or Versamune-HPV16, in combination with two investigational immune-modulating agents: bintrafusp alfa, or M7824, a bifunctional "trap" fusion protein targeting TGF-beta and PD-L1, and NHS-IL12, or M9241, a tumor-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16, or HPV16-positive cancers, by activating the immune system to produce in vivo CD8+ T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing. The presentation includes data from a total of 25 patients with data available as of the time of presentation submission, an update on the data previously reported for the original fourteen HPV16-positive patients who were in the subject of the abstract published on May 19th; an additional seven HPV16-negative patients who were not discussed in the abstract, and an additional four HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.

ShowHide Related Items >><<
PDSB PDS Biotechnology
$9.39 /

-3.37 (-26.41%)

PDSB PDS Biotechnology
$9.39 /

-3.37 (-26.41%)

06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
03/19/21 H.C. Wainwright
PDS Biotechnology price target raised to $8 from $6 at H.C. Wainwright
11/10/20 H.C. Wainwright
PDS Biotechnology upgraded to Buy from Neutral at H.C. Wainwright
PDSB PDS Biotechnology
$9.39 /

-3.37 (-26.41%)

  • 11
    Aug
PDSB PDS Biotechnology
$9.39 /

-3.37 (-26.41%)

Hot Stocks
PDS Biotechnology Corp trading resumes  15:36
06/07/21
06/07
15:36
06/07/21
15:36
PDSB

PDS Biotechnology

$11.38 /

-1.38 (-10.82%)

 
ShowHide Related Items >><<
PDSB PDS Biotechnology
$11.38 /

-1.38 (-10.82%)

PDSB PDS Biotechnology
$11.38 /

-1.38 (-10.82%)

06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
03/19/21 H.C. Wainwright
PDS Biotechnology price target raised to $8 from $6 at H.C. Wainwright
11/10/20 H.C. Wainwright
PDS Biotechnology upgraded to Buy from Neutral at H.C. Wainwright
PDSB PDS Biotechnology
$11.38 /

-1.38 (-10.82%)

  • 11
    Aug
PDSB PDS Biotechnology
$11.38 /

-1.38 (-10.82%)

Hot Stocks
PDS Biotechnology Corp trading halted, volatility trading pause  15:31
06/07/21
06/07
15:31
06/07/21
15:31
PDSB

PDS Biotechnology

$11.41 /

-1.35 (-10.58%)

 
ShowHide Related Items >><<
PDSB PDS Biotechnology
$11.41 /

-1.35 (-10.58%)

PDSB PDS Biotechnology
$11.41 /

-1.35 (-10.58%)

06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
05/20/21 Chardan
PDS Biotechnology price target raised to $11 from $10 at Chardan
03/19/21 H.C. Wainwright
PDS Biotechnology price target raised to $8 from $6 at H.C. Wainwright
11/10/20 H.C. Wainwright
PDS Biotechnology upgraded to Buy from Neutral at H.C. Wainwright
PDSB PDS Biotechnology
$11.41 /

-1.35 (-10.58%)

  • 11
    Aug
PDSB PDS Biotechnology
$11.41 /

-1.35 (-10.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.